Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

New research uncovers biological ties between obesity and asthma

Genes linked to chronic inflammation in asthma may be more active in people who are obese, according to new research that uncovers several biological ties between obesity and asthma.

19 Jul 2013

Virginia Commonwealth University receives $1.8M grant to study biology of allergic disease

The National Institutes of Health has awarded Virginia Commonwealth University a grant totaling $1.8 million to study the biology of allergic disease - work which may one day point researchers to the development of therapies to fight asthma, allergy and inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and heart disease.

18 Jul 2013

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.

11 Jul 2013

New mechanism triggers chronic inflammation in Alzheimer's, atherosclerosis and type-2 diabetes

Researchers at NYU Langone Medical Center have discovered a mechanism that triggers chronic inflammation in Alzheimer's, atherosclerosis and type-2 diabetes. The results, published today in Nature Immunology, suggest a common biochemical thread to multiple diseases and point the way to a new class of therapies that could treat chronic inflammation in these non-infectious diseases without crippling the immune system.

2 Jul 2013

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Idera Pharmaceuticals, Inc. announced results of a Phase 1 clinical trial of IMO-8400, a first-in-class antagonist of Toll-like Receptors 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases.

2 Jul 2013

New procedure to treat acid reflux can prevent chronic rejection in lung transplant patients

A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients.

30 Jun 2013

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.

28 Jun 2013

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

Study findings first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA.

14 Jun 2013

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).

13 Jun 2013

Clinical trial underway for potential new treatment for type 1 diabetes

A clinical trial is underway for a potential new treatment for type 1 diabetes that could eventually mean patients are able to reduce insulin treatment from several times a day to only once or twice a week. The new treatment is a direct result of research to understand the genetics of the disease.

11 Jun 2013

Poor sleep may be most harmful to women with coronary heart disease, study finds

Many women get too little sleep, despite considerable evidence showing the importance of sleep to overall health. Now a new UC San Francisco study has discovered another reason why inadequate sleep may be harmful, especially to women and their hearts.

5 Jun 2013

Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

Six of the top scientists studying psoriasis-the most common autoimmune disease in the country, affecting 7.5 million Americans-and psoriatic arthritis, an inflammatory joint and tendon disease affecting up to 30 percent of people with psoriasis, received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for these chronic diseases.

5 Jun 2013

Lupus Foundation of America announces Career Development Award and new summer fellowships

The Lupus Foundation of America, the only national force dedicated to solving the cruel mystery of lupus, announced recipients of five new summer fellowships and the Foundation's first-ever Career Development Award.

3 Jun 2013

Researchers show interleukin-22 guards against bacterial superinfections that can arise after influenza

Researchers from the Pasteur Institute, Lille, France have shown in a mouse model that interleukin-22 protects against bacterial superinfections that can arise following influenza.

31 May 2013

Systemic inflammation is linked with depression in COPD patients, say researchers

Depression is common in patients with chronic obstructive pulmonary disease (COPD) and has been linked with disease severity and impaired quality of life. Now, for the first time, researchers at the University of Pittsburgh have linked the systemic inflammation associated with COPD with depression in these patients.

22 May 2013

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

17 May 2013

Implications for manipulating immune response for some inflammatory disorders

Cytokines are molecules produced by immune cells that induce the migration of other cells to sites of infection or injury, promote the production of anti-microbial agents, and signal the production of inflammatory mediators.

14 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.

9 May 2013

Researcher looks for markers of sleep loss in humans

For years, Paul Shaw, PhD, a researcher at Washington University School of Medicine in St. Louis, has used what he learns in fruit flies to look for markers of sleep loss in humans.

4 May 2013